ABOUT US
NEWS
INVESTOR RELATIONS
简
繁
EN
ABOUT US
NEWS
INVESTOR RELATIONS
简
繁
EN
简
繁
EN
COMPANY NEWS
Essex Biotechnology Secures Exclusive Global Rights and Interests of SkQ1 in the field Ophthalmology from Mitotech
2022.10.13
Essex Bio-Technology Included in "Forbes Asia's Best Under A Billion 2022”
2022.08.15
EssexBio awarded “2021 China Pharmaceutical Industry Top 100 Series List” and “2022 China Pharmaceutical Brands List”
2022.07.15
Time
Last 7 days
Last 30 days
The last six months
Date
Title
2022-10-13
Essex Biotechnology Secures Exclusive Global Rights and Interests of SkQ1 in the field Ophthalmology from Mitotech
2022-08-24
Essex Bio-Technology (1061.HK) 2022 Interim Results at a Glance
2022-08-23
Essex Bio-Technology Announces 2022 Interim Financial Results
2022-08-15
Essex Bio-Technology Included in "Forbes Asia's Best Under A Billion 2022”
2022-07-15
EssexBio awarded “2021 China Pharmaceutical Industry Top 100 Series List” and “2022 China Pharmaceutical Brands List”
2022-05-07
Essex Bio-Technology attends the 2022 GRC-FGF Conference, with two cutting-edge scientific research accepted by GRC
2022-04-29
Essex Bio-Technology Announces Upcoming Presentation at ARVO 2022 Annual Meeting
2022-04-19
First Patient in Australia Dosed in a Global Multicentre Phase 3 Clinical Study of Bevacizumab for treatment of Ophthalmic Diseases
<
1
2
3
4
5
6
7
>